163 related articles for article (PubMed ID: 37442994)
41. MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1.
Chang Y; Cui M; Fu X; Zhang L; Li X; Li L; Wu J; Sun Z; Zhang X; Li Z; Nan F; Yan J; Zhang M
Cancer Biol Ther; 2019; 20(1):31-41. PubMed ID: 30299211
[TBL] [Abstract][Full Text] [Related]
42. Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest.
Schaaf L; Schwab M; Ulmer C; Heine S; Mürdter TE; Schmid JO; Sauer G; Aulitzky WE; van der Kuip H
Cancer Res; 2016 May; 76(10):2868-75. PubMed ID: 27013194
[TBL] [Abstract][Full Text] [Related]
43. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
[TBL] [Abstract][Full Text] [Related]
44. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
[TBL] [Abstract][Full Text] [Related]
45. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
[TBL] [Abstract][Full Text] [Related]
46. The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
Wichmann C; Klotz DM; Zeiler HJ; Hilger RA; Grützmann K; Krüger A; Aust D; Wimberger P; Kuhlmann JD
Gynecol Oncol; 2020 Dec; 159(3):850-859. PubMed ID: 32980128
[TBL] [Abstract][Full Text] [Related]
47. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
Cerrato A; Morra F; Celetti A
J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
[TBL] [Abstract][Full Text] [Related]
48. Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines.
Gabano E; Pinton G; Balzano C; Boumya S; Osella D; Moro L; Ravera M
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443328
[TBL] [Abstract][Full Text] [Related]
49. Expression of cell adhesion molecules and chemokine receptors: angioinvasiveness in nasal NK/T-cell lymphoma.
Liu A; Nakatsuka S; Yang WI; Kojya S; Aozasa K
Oncol Rep; 2005 Apr; 13(4):613-20. PubMed ID: 15756432
[TBL] [Abstract][Full Text] [Related]
50. Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody.
Agostinelli C; Paterson JC; Gupta R; Righi S; Sandri F; Piccaluga PP; Bacci F; Sabattini E; Pileri SA; Marafioti T
Histopathology; 2012 Jul; 61(1):33-46. PubMed ID: 22394247
[TBL] [Abstract][Full Text] [Related]
51. p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors.
Cañedo EC; Totten S; Ahn R; Savage P; MacNeil D; Hudson J; Autexier C; Deblois G; Park M; Witcher M; Ursini-Siegel J
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33470989
[TBL] [Abstract][Full Text] [Related]
52. Poly(ADP-Ribose) Polymerase-1 Inhibitors Drug Discovery, Design, and Development as Anticancer Agents from Past to Present: A Mini-Review.
AlGhamdi A; AlMubayedh H
Mini Rev Med Chem; 2022; 22(12):1597-1606. PubMed ID: 34587882
[TBL] [Abstract][Full Text] [Related]
53. PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
Moutafi M; Economopoulou P; Rimm D; Psyrri A
Oral Oncol; 2021 Jun; 117():105292. PubMed ID: 33862558
[TBL] [Abstract][Full Text] [Related]
54. PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth.
Bhattacharjee S; Sullivan MJ; Wynn RR; Demagall A; Hendrix AS; Sindhwani P; Petros FG; Nadiminty N
BMC Cancer; 2022 Mar; 22(1):312. PubMed ID: 35321693
[TBL] [Abstract][Full Text] [Related]
55. Combinatorial Treatment with PARP-1 Inhibitors and Cisplatin Attenuates Cervical Cancer Growth through Fos-Driven Changes in Gene Expression.
Gupte R; Lin KY; Nandu T; Lea JS; Kraus WL
Mol Cancer Res; 2022 Aug; 20(8):1183-1192. PubMed ID: 35503086
[TBL] [Abstract][Full Text] [Related]
56. Olaparib-Resistant
Biegała Ł; Gajek A; Marczak A; Rogalska A
Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
[TBL] [Abstract][Full Text] [Related]
57. Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
Shim JI; Ryu JY; Jeong SY; Cho YJ; Choi JJ; Hwang JR; Choi JY; Sa JK; Lee JW
Gynecol Oncol; 2022 May; 165(2):270-280. PubMed ID: 35305818
[TBL] [Abstract][Full Text] [Related]
58. HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer.
Ma H; Qi G; Han F; Lu W; Peng J; Li R; Yan S; Yuan C; Kong B
Cell Death Dis; 2022 Mar; 13(3):263. PubMed ID: 35332131
[TBL] [Abstract][Full Text] [Related]
59. ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer.
McMellen A; Yamamoto TM; Qamar L; Sanders BE; Nguyen LL; Ortiz Chavez D; Bapat J; Berning A; Post MD; Johnson J; Behbakht K; Nurmemmedov E; Chuong EB; Bitler BG
Mol Cancer Res; 2023 Jan; 21(1):3-13. PubMed ID: 36149636
[TBL] [Abstract][Full Text] [Related]
60.
Xu B; Jiang L; Cui JL; Zhu XL; Bai YJ; Chen J; Diao YQ
Ann Transl Med; 2022 Dec; 10(23):1276. PubMed ID: 36618816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
